Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: William Partmann who wrote (1198)	1/14/2000 9:18:00 AM
From: William Partmann	Read Replies (1) \| Respond to of 1686

RESEARCH ALERT - Biogen raised to buy CHICAGO, Jan 14 (Reuters) - ABN AMRO said Friday it had raised its rating on drug company Biogen Inc. to buy from outperform. -- raised its 2000 earnings estimate by 23 cents to $1.90 a share, compared with $1.46 a share in 1999. The 2001 estimate is $2.35 a share, ABN AMRO said. -- set its new price target at $99. -- said sales of the company's multiple sclerosis drug Avonex continue to benefit from market expansion and earlier use in patients. -- Biogen closed at 77-5/16 Thursd